DK2096167T3 - Aptamer mod midkin og anvendelse deraf - Google Patents

Aptamer mod midkin og anvendelse deraf

Info

Publication number
DK2096167T3
DK2096167T3 DK07831829.2T DK07831829T DK2096167T3 DK 2096167 T3 DK2096167 T3 DK 2096167T3 DK 07831829 T DK07831829 T DK 07831829T DK 2096167 T3 DK2096167 T3 DK 2096167T3
Authority
DK
Denmark
Prior art keywords
midkin
aptamer against
aptamer
against midkin
Prior art date
Application number
DK07831829.2T
Other languages
English (en)
Inventor
Shin Miyakawa
Masatoshi Fujiwara
Yoshikazu Nakamura
Takashi Matsui
Sadatoshi Sakuma
Original Assignee
Ribomic Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ribomic Inc filed Critical Ribomic Inc
Application granted granted Critical
Publication of DK2096167T3 publication Critical patent/DK2096167T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/317—Chemical structure of the backbone with an inverted bond, e.g. a cap structure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3515—Lipophilic moiety, e.g. cholesterol
DK07831829.2T 2006-11-14 2007-11-14 Aptamer mod midkin og anvendelse deraf DK2096167T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2006308482 2006-11-14
PCT/JP2007/072099 WO2008059877A1 (fr) 2006-11-14 2007-11-14 Aptamère contre la midkine et son utilisation

Publications (1)

Publication Number Publication Date
DK2096167T3 true DK2096167T3 (da) 2013-02-04

Family

ID=39401681

Family Applications (1)

Application Number Title Priority Date Filing Date
DK07831829.2T DK2096167T3 (da) 2006-11-14 2007-11-14 Aptamer mod midkin og anvendelse deraf

Country Status (27)

Country Link
US (1) US8080649B2 (da)
EP (1) EP2096167B1 (da)
JP (1) JP5190573B2 (da)
KR (1) KR101516024B1 (da)
CN (1) CN101573446B (da)
AU (1) AU2007320401B2 (da)
BR (1) BRPI0718913A2 (da)
CA (1) CA2669523C (da)
CO (1) CO6190535A2 (da)
CY (1) CY1113679T1 (da)
DK (1) DK2096167T3 (da)
ES (1) ES2397715T3 (da)
HK (1) HK1135729A1 (da)
HR (1) HRP20130012T1 (da)
IL (1) IL198705A (da)
MX (1) MX2009005148A (da)
MY (1) MY147374A (da)
NO (1) NO342010B1 (da)
NZ (1) NZ577396A (da)
PL (1) PL2096167T3 (da)
PT (1) PT2096167E (da)
RU (1) RU2460794C2 (da)
SI (1) SI2096167T1 (da)
TW (1) TWI481713B (da)
UA (1) UA100847C2 (da)
WO (1) WO2008059877A1 (da)
ZA (1) ZA200903562B (da)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1964574B1 (en) 2005-11-14 2016-09-07 Cellmid Limited Method for treatment or prevention of disease associated with functional disorder of regulatory t cell
EP2354225B1 (en) 2008-09-24 2015-04-22 Ribomic Inc. Aptamer for ngf and use thereof
JP6041373B2 (ja) * 2010-02-01 2016-12-07 Ｎｅｃソリューションイノベータ株式会社 ＴＮＦ−αに結合するアプタマー分子
SI2551346T1 (sl) * 2010-03-24 2016-05-31 Ribomic Inc. Aptamer za NGF in njegova uporaba
RU2555509C2 (ru) 2010-12-20 2015-07-10 Колгейт-Палмолив Компани Инкапсулированная в желатине композиция для ухода за полостью рта, содержащая гидрофильный активный ингредиент, гидрофобный структурирующий ингредиент и масляный носитель
AU2012317323B2 (en) * 2011-09-28 2017-10-05 Fujimoto Pharmaceutical Corporation NGF aptamer and application thereof
JP6020888B2 (ja) * 2012-06-29 2016-11-02 国立大学法人名古屋大学 エポキシエイコサトリエン酸関連疾患の予防又は治療
JP6352810B2 (ja) * 2012-11-21 2018-07-04 大塚製薬株式会社 ミッドカインに対するアプタマー及びその用途
RU2549704C1 (ru) * 2014-03-26 2015-04-27 Федеральное государственное бюджетное учреждение науки Институт химической биологии и фундаментальной медицины Сибирского отделения Российской академии наук (ИХБФМ СО РАН) Рнк-аптамер, обладающий способностью узнавать характерные для рассеянного склероза аутоантитела
CA3027626A1 (en) 2016-07-01 2018-01-04 Somalogic, Inc. Oligonucleotides comprising modified nucleosides
KR101985300B1 (ko) * 2016-07-19 2019-06-03 삼성전자주식회사 미드카인 저해제를 포함하는 뇌종양 치료 또는 예방용 약학 조성물
CN109536505B (zh) * 2018-12-07 2021-11-09 暨南大学 鬼臼毒素的核酸适配体及其应用
EP3894423A4 (en) * 2018-12-14 2022-10-12 Board of Regents, The University of Texas System DNA APTAMERS AND THEIR USE TO TREAT CANCER
WO2020241493A1 (ja) * 2019-05-24 2020-12-03 株式会社リボミック 骨形成や骨代謝の異常に関連する疾患の治療薬

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5660985A (en) 1990-06-11 1997-08-26 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands containing modified nucleotides
JP3842304B2 (ja) 1992-10-08 2006-11-08 喬 村松 癌の診断、治療薬
DE69835016T2 (de) * 1997-07-14 2007-06-28 Muramatsu, Takashi, Nagoya Verwendung von midkin oder von anti-midkin antikörper
WO2000010608A1 (fr) 1998-08-24 2000-03-02 Meiji Milk Products Co., Ltd. Medicament pour le traitement et/ou la prevention de l'arteriosclerose et de la reangiostenose post-actp
US6858390B2 (en) * 1998-12-31 2005-02-22 Ingeneus Corporation Aptamers containing sequences of nucleic acid or nucleic acid analogues bound homologously, or in novel complexes
JP2000354487A (ja) * 1999-06-15 2000-12-26 Takashi Muramatsu ミッドカイン受容体
JP4768440B2 (ja) 2003-03-06 2011-09-07 セルミド リミテッド 開腹手術後の癒着の予防剤
WO2004085642A1 (ja) * 2003-03-27 2004-10-07 Takashi Muramatsu 関節炎関連遺伝子及びこれの関節炎検査等への利用
JP3940097B2 (ja) * 2003-05-20 2007-07-04 株式会社リボミック 翻訳開始因子ｅＩＦ４Ｅに結合するリガンド
JP2007297282A (ja) 2004-08-13 2007-11-15 Cell Signals Inc 子宮内膜症の発生の際にミッドカインによって起こる影響
JP2006141305A (ja) * 2004-11-22 2006-06-08 Univ Of Tokyo 翻訳開始因子ｅＩＦ４Ｇに結合するリボ核酸
JP2006211905A (ja) * 2005-02-01 2006-08-17 Univ Of Tokyo 腫瘍壊死因子受容体ファミリータンパク質に結合する核酸リガンド
JP2006308482A (ja) 2005-04-28 2006-11-09 Sanyo Electric Co Ltd 検出装置

Also Published As

Publication number Publication date
NO20092280L (no) 2009-08-14
PT2096167E (pt) 2013-01-25
EP2096167A1 (en) 2009-09-02
RU2460794C2 (ru) 2012-09-10
RU2009122476A (ru) 2010-12-20
JPWO2008059877A1 (ja) 2010-03-04
AU2007320401A1 (en) 2008-05-22
CA2669523A1 (en) 2008-05-22
CO6190535A2 (es) 2010-08-19
HRP20130012T1 (hr) 2013-01-31
CN101573446B (zh) 2013-07-17
SI2096167T1 (sl) 2013-02-28
TWI481713B (zh) 2015-04-21
KR20090097879A (ko) 2009-09-16
IL198705A (en) 2014-11-30
BRPI0718913A2 (pt) 2013-12-10
KR101516024B1 (ko) 2015-04-29
PL2096167T3 (pl) 2013-03-29
JP5190573B2 (ja) 2013-04-24
IL198705A0 (en) 2011-08-01
MY147374A (en) 2012-11-30
NZ577396A (en) 2011-12-22
CN101573446A (zh) 2009-11-04
ES2397715T3 (es) 2013-03-08
UA100847C2 (uk) 2013-02-11
US8080649B2 (en) 2011-12-20
TW200831668A (en) 2008-08-01
EP2096167B1 (en) 2012-10-17
CY1113679T1 (el) 2016-06-22
WO2008059877A1 (fr) 2008-05-22
CA2669523C (en) 2016-06-21
EP2096167A4 (en) 2009-11-11
HK1135729A1 (en) 2010-06-11
ZA200903562B (en) 2010-07-28
NO342010B1 (no) 2018-03-12
AU2007320401B2 (en) 2012-12-06
US20100004432A1 (en) 2010-01-07
MX2009005148A (es) 2009-08-24

Similar Documents

Publication Publication Date Title
DK2096167T3 (da) Aptamer mod midkin og anvendelse deraf
DK2170827T3 (da) Indolin-2-oner og aza-indolin-2-oner
DK2001556T3 (da) Thioninium-forbindelser og anvendelse deraf
DK2185552T3 (da) Dipeptoid-prodrugs og anvendelse heraf
DK2118140T3 (da) Humancytomegalovirus-neutraliserende antistoffer og anvendelse deraf
BRPI0907231A2 (pt) pirrolpirimidinas e pirrolpiridinas
DK1954140T3 (da) Glycerollevulinatketaler og deres anvendelse
DK3263589T5 (da) Peptidsekvenser og sammensætninger
DE602007010795D1 (de) Blattsauger und -häcksler
DK2160401T3 (da) Fusionsmolekyler og il-15-varianter
DK2185164T3 (da) Sammensætning og terapeutisk antitumorvaccine
DK2041138T3 (da) Pyrroltriazinkinase-inhibitorer
DK2079485T3 (da) Phenylpropionamidforbindelser og anvendelsen deraf
DK2081955T3 (da) Metastinderivater og anvendelse deraf
DK2349430T3 (da) KATETERISERINGANORDNING og -kit
DK2024375T3 (da) Cyclopropyl-kondenserede indolobenzazepin-HCV-NS5B-hæmmere
DK2376791T3 (da) Afstandsindretning og fastgørelsesindretning med afstandsindretning
DK1894567T3 (da) Ledsagende farmaceutiske midler og anvendelse deraf
DK3020729T3 (da) Antistoffer mod human il-22 og anvendelser deraf
DK2038275T3 (da) Ny pyridazinforbindelse og anvendelse heraf
DK3338790T3 (da) Oligopeptid-forbindelser og anvendelser deraf
DK2049571T3 (da) Bindingsmidler, der er målrettet mod PDGFR-ALFA, og anvendelser deraf
DK2160336T3 (da) Forbindelsesmekanisme og fremgangsmåde
DK2190991T3 (da) SDF-1-Bindende nucleinsyrer og anvendelsen deraf
DK1885716T3 (da) Thiazolderivater og anvendelse deraf